ArticleMedicine2026
Thirty-year transition of disease burden attributed to low bone mineral density: A disaggregated analysis of Global Patterns and China's Epidemiological Profile (1990-2021).
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
This study aims to compare the disease burden of low bone mineral density (LBMD) between China and global populations from 1990 to 2021 and quantify the associations of sex, age, and socio-demographic index with disability-adjusted life years (DALYs). A secondary analysis of LBMD was conducted using comprehensive data from the Global Burden of Disease Study 2021. The absolute number of DALYs and DALYs rates were determined for 1990 and 2021. Joinpoint regression analysis was employed to assess trends in the age-standardized DALYs rate from 1990 to 2021 and over the most recent decade (2012-2021), using the average annual percentage change. Additionally, China's future trends over the next 20 years were projected based on this analysis. In 2021, LBMD accounted for 17.31 million global DALYs and 3.47 million (95% UI: 2.78-4.24) in China. Despite a decline in China's age-standardized rate (from 195 to 175 per 1,00,000; average annual percentage change = -0.29%; 95% CI: -0.32 to -0.25), the absolute DALYs more than doubled. The most pronounced increase occurred in adults aged ≥80 years, with older women exhibiting rates 22.5% higher than men. Projections indicate a rise in China's rate from 175 to 210 per 1,00,000 by 2050, starting in approximately 2040. Women, older adults, and populations in low-middle and middle socio-demographic index regions are high-risk groups that require prioritized attention. These findings highlight the need for age-stratified screening protocols and context-specific resource allocation in low-middle SDI regions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.